CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications
Source link
Rayzon Solar Ranks Second in India's Module Shipments with 7.21% Share in FY26
